Barasertib (AZD1152-HQPA)

For research use only. Not for use in humans.

目录号:S1147 别名: AZD2811 中文名称:巴拉塞替

Barasertib (AZD1152-HQPA) Chemical Structure

CAS No. 722544-51-6

Barasertib (AZD1152-HQPA, AZD2811) 是一种高度选择性的Aurora B抑制剂,无细胞试验中IC50为0.37 nM,作用于Aurora B比作用于Aurora A选择性高3700倍左右。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1375.46 现货
RMB 976.12 现货
RMB 3169.53 现货
RMB 5477.43 现货
RMB 7944.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Barasertib (AZD1152-HQPA)发表文献81篇:

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Barasertib (AZD1152-HQPA, AZD2811) 是一种高度选择性的Aurora B抑制剂,无细胞试验中IC50为0.37 nM,作用于Aurora B比作用于Aurora A选择性高3700倍左右。
靶点
Aurora B [1]
(Cell-free assay)
0.37 nM
体外研究

AZD1152作用于Aurora B比作用于Aurora A选择性高3000多倍,IC50为1.368 μM。AZD1152作用于50种其他丝-苏氨酸和酪氨酸激酶,包括FLT3, JAK2, 和 Abl活性更低。AZD1152 抑制造血恶性细胞增殖,如HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, 和K562细胞,IC50为3-40 nM,效果比另一种Aurora激酶抑制剂ZM334739高100多倍,IC50为3-30 μM。AZD1152抑制MOLM13和MV4-11细胞克隆生长,IC50分别为1 nM和2.8 nM,也抑制新分离的抗Imatinib的白血病细胞,IC50 为1-3 nM, 比作用于骨髓单核细胞更有效,IC50>10 nM。AZD1152 诱导携带 4N/8N DNA的细胞累积,随后凋亡,这种作用存在剂量和时间依赖性。 [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP NXv6NlBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWiwMVUxOCCwTR?= M4HpOFQ5yqCq MUDJR|UxRTJ3IH7N NFjR[pQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Y2QSd-MkWyO|c3PTl:L3G+
LNCaP NUPhWZN6SXCxcITvd4l{KEG|c3H5 NHXVe2wxNTVyMDDuUS=> NGKyRos1QMLiaB?= MlfpbY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bEB1cHKxdXfoJINie3Cjc3WtN{B2eHKnZ4XsZZRqd25? NV;mfIFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c3PTlpPkK1Nlc4PjV7PD;hQi=>
LNCaP M4XqSmZ2dmO2aX;uJGF{e2G7 MlfuOVAhdk1? MYm0PEBp MmrLbY5lfWOnczDtbYNzd263Y3zlbUB4cXSqIHHu[ZVo\W6rYzDt[YNp[W6rc32= Mn7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e2OVkoRjJ3Mke3OlU6RC:jPh?=
Ramos NEW2UYxHfW6ldHnvckBCe3OjeR?= MX21NFAhdk1? NYCwdJB3OC15MjDo Ml;UbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Daudi  NFH6VoVHfW6ldHnvckBCe3OjeR?= MmjjOVAxKG6P NHvGSYQxNTd{IHi= M1O3SYlvcGmkaYTzJGF2em:{YTDCJItqdmG|ZR?= M1TkflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L540 NFTNbI5HfW6ldHnvckBCe3OjeR?= MXu1NFAhdk1? NXjaNJFjOC15MjDo Mo\IbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
BJAJ M3znS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:1NFAhdk1? M3vPblAuPzJiaB?= NHr1NlZqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MkPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Ramos NFnmTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV21NFAhdk1? M2LM[lAuPzJiaB?= NWe2cVV2cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> NV;JZW9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Raji M2PQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDRbG86PTByIH7N MkHzNE04OiCq M2Lad4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= NIPmepA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  NYLxO2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjMZ2J[PTByIH7N NF3NbHAxNTd{IHi= MlWwbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NEW0dG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L428 M1fVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPIXWM2ODBibl2= MlTSNE04OiCq MkXZbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXrrXW5sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
KM-H2 NGfFd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK2[Zl4PTByIH7N NID6R4kxNTd{IHi= MkXDbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3PrWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
HDLM-2 M3ywUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV21NFAhdk1? NGXE[4cxNTd{IHi= M3jxPIlvcGmkaYTzJINmdGxiZ4Lve5Rp M3zvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L450 M2PNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iySlUxOCCwTR?= NV;nWndtOC15MjDo M2jYSYlvcGmkaYTzJINmdGxiZ4Lve5Rp MnvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
BJAJ M2KzPGFxd3C2b4Ppd{BCe3OjeR?= NHPjdYI2ODBibl2= MkjFNE04OiCq NXHyOFJ7cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Ramos NGjlcGdCeG:ydH;zbZMhSXO|YYm= NVT6VVNxPTByIH7N NV3ROFN5OC15MjDo Moj0bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MnTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Raji M1rYTmFxd3C2b4Ppd{BCe3OjeR?= NEe2TFg2ODBibl2= NF6wNXAxNTd{IHi= MoDxbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NFG2VJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  MnS4RZBweHSxc3nzJGF{e2G7 Mki2OVAxKG6P M1fmVlAuPzJiaB?= NH\Ebm1qdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NWTq[Zh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
L428 MUPBdI9xfG:|aYOgRZN{[Xl? NVniSYNwPTByIH7N M3PJTlAuPzJiaB?= NFPuVpFqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NXvlVYNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
KM-H2 NVPi[3VvSXCxcITvd4l{KEG|c3H5 NXnYfmsyPTByIH7N M{KyOFAuPzJiaB?= MXvpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MlLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
HDLM-2 NXTH[ppHSXCxcITvd4l{KEG|c3H5 M2S1dVUxOCCwTR?= MlLJNE04OiCq NXHFToVmcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M3;4S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L450 NWjUcVV4SXCxcITvd4l{KEG|c3H5 MlnnOVAxKG6P MlzKNE04OiCq M2DGNIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
SW620 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHFR|UxRTFywsGyMlEhdk1? MlTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{NEWwPVAoRjJzMkS1NFkxRC:jPh?=
HCT116 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXFR|UxRTFzwsGzMlMhdk1? MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{NEWwPVAoRjJzMkS1NFkxRC:jPh?=
MDA-MB-435 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuwMVExODByIH7N NYfHTmIzOi13IHS= NULFVll{TE2VTx?= MXfJR|UxRTF{NTDuUS=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-468 M3nMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMVExODByIH7N M4rtOFIuPSCm NFvYSnZFVVOR M3jlR2lEPTB;MUSgcm0> NITR[XQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-231 NFPyZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDrR4kxNTFyMECwJI5O M1TMXFIuPSCm NVj4Zo1xTE2VTx?= M3zkNmlEPTB;MUC1JI5O MkLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
BT474 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuwMVExODByIH7N NUnCfW9qOi13IHS= MnzOSG1UVw>? Mn7wTWM2OD16IH7N NYLZbZN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
MDA-MB-361 M3TIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrUFAuOTByMECgcm0> MXmyMVUh\A>? MnrWSG1UVw>? MV\JR|UxRTdyIH7N NHPuRVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
HER18 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrCVJlyOC1zMECwNEBvVQ>? Mn[3Nk02KGR? MWfEUXNQ MUHJR|UxRTJyIH7N MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
HER18 MYjBdI9xfG:|aYOgRZN{[Xl? NHzrNIoyODBibl2= MnrVNE8zPC92ODDo MmqzSG1UVw>? NGf5U2ZqdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?= M2H6d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-231 NGK2cWFCeG:ydH;zbZMhSXO|YYm= NXLLNnR4OTB3IH7N NUKyUHVqOC9{ND:0PEBp M{fLPGROW09? NEjFWm5qdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?= NHe5XHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
JHH-1 NYPqbGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H4c|AvO+LCk{GwNFDDqG6P NYezTWQ2PzJiaB?= NXjjO3V{TUN3ME2xO{41yrFzLkCgcm0> M13pNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
JHH-2 M2C3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\pZVAvO+LCk{GwNFDDqG6P M3fvVFczKGh? M{T3eWVEPTB;MkG4MlDDuTFyLkigcm0> NWnFRlh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
JHH-4 NI\OboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrRfIcxNjQkgKOxNFAxyqCwTR?= M1u2bFczKGh? MmPHSWM2OD1zNUWuOuKyOTZwODDuUS=> NFHKZlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
HuH-1 NV3UXGJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGwMlPjiJNzMECwxsBvVQ>? M4jZTFczKGh? MnzsSWM2OD1{Nz6zxtE2NjBibl2= M2nRV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-6 M4TmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW3NE4{6oDVMUCwNOKhdk1? MkfsO|IhcA>? NUPifHZyTUN3ME2zMlfDuTBwNjDuUS=> MmLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HuH-7 M{TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvZb3FlOC5|4pETNVAxOMLibl2= M3LNTlczKGh? NF7TcGlGSzVyPU[uPOKyOC5|IH7N M1z5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HLE NYPDU5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jtN|AvO+LCk{GwNFDDqG6P M3LqXFczKGh? NFT0fW9GSzVyPUS1MlnDuTZwNDDuUS=> NIjZZY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
HLF MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LESVAvO+LCk{GwNFDDqG6P M4LjcVczKGh? MnvaSWM2OD1zMk[uNeKyOTJwMjDuUS=> Mn\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
PLC/PRF/5 NFvGT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrMT2UxNjQkgKOxNFAxyqCwTR?= MlzTO|IhcA>? MnrlSWM2OD15Nj65xtE6Njlibl2= NGjTNJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
SK-Hep1 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XWW|AvO+LCk{GwNFDDqG6P Ml3mO|IhcA>? MlrqSWM2OD1{MT65xtEyNjJibl2= NW\z[GNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
Hep3B MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqwMlPjiJNzMECwxsBvVQ>? MneyO|IhcA>? M3HaT2VEPTB;Nz62xtEyNjJibl2= MmTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HepG2 NHPzW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWewMlPjiJNzMECwxsBvVQ>? M1Lt[VczKGh? M2LiW2VEPTB;MUSuO:KyOS55IH7N NWHvZlNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
Ramos MmL4RZBweHSxc3nzJGF{e2G7 NVrjNFdMOjVxNUCvNVAxKG6P Ml31OFghcA>? NGTXOHFqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> NEjHd3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN|E3QCd-MUm4NlMyPjh:L3G+
Daudi  M2nNVWFxd3C2b4Ppd{BCe3OjeR?= NVfHNGxZOjVxNUCvNVAxKG6P M{fNclQ5KGh? NVTYVphocW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{ NHjYcIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN|E3QCd-MUm4NlMyPjh:L3G+
BALM-14 M1njZmFxd3C2b4Ppd{BCe3OjeR?= NXvDbZpoOTJwNT:yOU82OCCwTR?= NITWNmw1QCCq M1y5e4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> M4XNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
BALM-27 NEHCcIFCeG:ydH;zbZMhSXO|YYm= NXeyUXV3OTJwNT:yOU82OCCwTR?= NFjZWXA1QCCq MU\pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= M{P5NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
NB4 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m4NlAvODFxMD6xM|Eh|ryP M1rqUlQ5KGh? MorPbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NV7Bcm02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOlc1QDRpPkG4N|Y4PDh2PD;hQi=>
HeLa M33Hd2Z2dmO2aX;uJGF{e2G7 MmDaNUB2VQ>? NXXNV2RKOjRiaILz M4H5emlvcGmkaYTpc44hd2ZiYYXyc5JiKEJiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDFidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmd? MnrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1OFkoRjJyNki0OVQ6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN; 

PubMed: 26497213     


Downstream effects of barasertib-induced AURKB inhibition on histone H3 phosphorylation and TP53 protein levels in IMR5 and SK-N-BE (2c) as indicated after 24h (left) and 48h (right). TP53 and its downstream effector CDKN1A were up-regulated by barasertib䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

p53 / p21 / p-p38 / p38 ; 

PubMed: 24782314     


U2OS cells were treated with 50 nm or 100 nm AZD1152 for 24 h. p21, p38, p-p38, and p53 levels were determined by immunoblotting β-actin served as a loading control.

26497213 24782314
Immunofluorescence
p21 ; 

PubMed: 24782314     


U2OS cells were treated as in H. Levels of p21 were analyzed by immunostaining. DNA was counterstained with Hoechst 33258.

24782314
Growth inhibition assay
Cell viability ; 

PubMed: 26497213     


Dose response curves to barasertib at 72h of incubation normalized to the DMSO control sample (mean ± SD, n = 5). The inset depicts the normalized AUCs of each response curve. 

26497213
体内研究 AZD1152 按25 mg/kg剂量单独处理MOLM13移植瘤,显著抑制肿瘤生长,平均肿瘤体积从1261 mm3 降低到 71 mm3,且平均肿瘤重量从583 mg降低到78 mg, 观察到坏死组织被吞噬细胞浸润。[1]此外, AZD1152 每天按10-150 mg/kg剂量处理多种人类实体移植瘤,包括 结肠癌,乳腺癌,和肺癌,显著抑制肿瘤生长,这种作用存在剂量依赖性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1,和 K562
  • Concentrations: 溶于 DMSO, 终浓度为~100 nM
  • Incubation Time: 24或48小时
  • Method: 使用不同浓度AZD1152处理细胞 24或 48小时。通过测量 3H-胸甘摄取(在收集前6小时,加入同位素)而测量细胞增殖,根据剂量-反应曲线计算IC50值。通过流式细胞仪分析细胞周期。通过膜联蛋白V–FITC凋亡检测试剂盒测量细胞凋亡。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 皮下注射MOLM13细胞的雌性免疫缺陷BALB/c裸鼠
  • Dosages: 5 或25 mg/kg
  • Administration: 腹腔注射,每周4次,或每隔一天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.96 mM)
Ethanol 3 mg/mL (5.91 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
7mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 507.56
化学式

C26H30FN7O3

CAS号 722544-51-6
储存条件 粉状
溶于溶剂
别名 AZD2811

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

  • 回答:

    S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)供应商 | 采购Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)价格 | Barasertib (AZD1152-HQPA)生产 | 订购Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID